[ad_1] STOCKHOLM, Oct. 27, 2025 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Leqembi® (lecanemab) for the treatment […]
Tag: BioArctic
Health Canada Grants Authorization for Leqembi® (lecanemab)
[ad_1] STOCKHOLM, Oct. 26, 2025 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Leqembi® (lecanemab) for the treatment […]
First patient dosed in EXIST Phase 2a study in Parkinson’s disease
[ad_1] STOCKHOLM , Dec. 5, 2024 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been dosed with exidavnemab in the EXIST Phase 2a study, in Parkinson’s disease patients. […]
First patient dosed in EXIST Phase 2a study in Parkinson’s disease
[ad_1] STOCKHOLM , Dec. 5, 2024 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been dosed with exidavnemab in the EXIST Phase 2a study, in Parkinson’s disease patients. […]
Leqembi® approved in Mexico
[ad_1] STOCKHOLM, Dec. 4, 2024 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved Leqembi (lecanemab) […]
